|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
956,580,000 |
Market
Cap: |
795.17(B) |
Last
Volume: |
2,536,282 |
Avg
Vol: |
3,278,293 |
52
Week Range: |
$434.7 - $815.06 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 720 |
Guru Rank Value : 1.4 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
656 |
Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
475,750 |
1,345,750 |
2,984,906 |
5,945,418 |
Total Sell Value |
$384,452,381 |
$992,137,761 |
$2,147,483,647 |
$2,147,483,647 |
Total People Sold |
2 |
2 |
4 |
6 |
Total Sell Transactions |
7 |
19 |
46 |
86 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Harrington Michael J |
Senior VP and General Counsel |
|
2019-02-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
62,500 |
47,800 |
|
- |
|
Conterno Enrique A |
SVP&Pres, LillyDiab & LillyUSA |
|
2019-02-04 |
4/A |
A |
$120.17 |
$3,206,376 |
D/D |
26,682 |
157,962 |
|
- |
|
Zakrowski Donald A |
Chief Accounting Officer |
|
2019-02-04 |
4/A |
A |
$120.17 |
$389,952 |
D/D |
3,245 |
6,595 |
|
- |
|
Smiley Joshua L |
SVP and CFO |
|
2019-02-04 |
4/A |
A |
$120.17 |
$1,196,292 |
D/D |
9,955 |
29,984 |
|
- |
|
Oneill Myles |
SVP & Pres., Mfg. Operations |
|
2019-02-04 |
4/A |
A |
$120.17 |
$1,032,621 |
D/D |
8,593 |
40,646 |
|
- |
|
Oneill Myles |
SVP & Pres., Mfg. Operations |
|
2019-02-04 |
4/A |
A |
$120.17 |
$563,597 |
I/I |
4,690 |
57,374 |
|
- |
|
Shah Aarti S. |
SVP & CIO |
|
2019-02-04 |
4/A |
A |
$120.17 |
$713,810 |
D/D |
5,940 |
20,225 |
|
- |
|
Harrington Michael J |
Senior VP and General Counsel |
|
2019-02-04 |
4/A |
A |
$120.17 |
$3,383,507 |
D/D |
28,156 |
126,300 |
|
- |
|
Fry Stephen F |
SVP, HR & Diversity |
|
2019-02-04 |
4/A |
A |
$120.17 |
$2,331,899 |
D/D |
19,405 |
124,510 |
|
- |
|
Norton Johna |
Senior VP, Global Quality |
|
2019-02-04 |
4/A |
A |
$120.17 |
$355,703 |
D/D |
2,960 |
20,819 |
|
- |
|
Zakrowski Donald A |
Chief Accounting Officer |
|
2019-02-04 |
4 |
A |
$120.17 |
$389,711 |
D/D |
3,243 |
6,593 |
|
- |
|
Oneill Myles |
SVP & Pres., Mfg. Operations |
|
2019-02-04 |
4 |
A |
$120.17 |
$1,032,501 |
D/D |
8,592 |
40,645 |
|
- |
|
Oneill Myles |
SVP & Pres., Mfg. Operations |
|
2019-02-04 |
4 |
A |
$120.17 |
$556,988 |
I/I |
4,635 |
57,319 |
|
- |
|
Smiley Joshua L |
SVP and CFO |
|
2019-02-04 |
4 |
A |
$120.17 |
$1,196,172 |
D/D |
9,954 |
29,983 |
|
- |
|
Ricks David A |
President & CEO |
|
2019-02-04 |
4 |
A |
$120.17 |
$3,192,556 |
D/D |
26,567 |
152,790 |
|
- |
|
White Anne E. |
SVP & Pres-Lilly Oncology |
|
2019-02-04 |
4 |
A |
$120.17 |
$870,752 |
D/D |
7,246 |
21,043 |
|
- |
|
Skovronsky Daniel |
SVP, CSO, and Pres. LRL |
|
2019-02-04 |
4 |
A |
$120.17 |
$1,876,935 |
D/D |
15,619 |
70,818 |
|
- |
|
Zulueta Alfonso G |
SVP & President, Lilly Intl |
|
2019-02-04 |
4 |
A |
$120.17 |
$2,550,488 |
D/D |
21,224 |
67,806 |
|
- |
|
Shah Aarti S. |
SVP & CIO |
|
2019-02-04 |
4 |
A |
$120.17 |
$713,690 |
D/D |
5,939 |
20,224 |
|
- |
|
Conterno Enrique A |
SVP&Pres, LillyDiab & LillyUSA |
|
2019-02-04 |
4 |
A |
$120.17 |
$3,206,256 |
D/D |
26,681 |
157,961 |
|
- |
|
Fry Stephen F |
SVP, HR & Diversity |
|
2019-02-04 |
4 |
A |
$120.17 |
$2,331,779 |
D/D |
19,404 |
124,509 |
|
- |
|
Norton Johna |
Senior VP, Global Quality |
|
2019-02-04 |
4 |
A |
$120.17 |
$355,463 |
D/D |
2,958 |
20,817 |
|
- |
|
Harrington Michael J |
Senior VP and General Counsel |
|
2019-02-04 |
4 |
A |
$120.17 |
$3,383,386 |
D/D |
28,155 |
126,299 |
|
- |
|
Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
|
2019-02-04 |
4 |
A |
$120.17 |
$890,580 |
D/D |
7,411 |
26,820 |
|
- |
|
Oneill Myles |
SVP & Pres., Mfg. Operations |
|
2019-02-01 |
4 |
D |
$119.86 |
$178,711 |
I/I |
(1,491) |
52,684 |
|
- |
|
1437 Records found
|
|
Page 30 of 58 |
|
|